higher predictive power for the risk of PDR pathogens than the presence of the risk factors or the HCAP criteria. Conclusions: Functional status, pulmonary comorbidity and previous exposure to the healthcare environment were significantly associated with acquiring PDR pathogens in immunocompetent patients with pneumonia that developed out of hospital. However, a risk stratification model was more accurate than the presence of the risk factors or the HCAP criteria for assessing the probability of PDR pathogens.
Introduction
Traditionally, pneumonia has been classified as a triad: community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and pneumonia in immunosuppressed patients, depending on the host's immunity and the pneumonia acquisition environment [1] . The distinction is considered relevant because the predictable microbiology and empirical treatment of these types of pneumonia differ. In 2005, the concept of healthcare-associated pneumonia (HCAP) was introduced by the American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) [2] . HCAP refers to pneumonia that occurs outside the hospital in immunocompetent patients with contact or exposure to the healthcare environ-ment [2] , i.e. patients who were potentially infected with multidrug-resistant bacteria, which is different from CAP but similar to HAP. The purpose of the HCAP concept is to identify patients who may be infected with highly resistant pathogens [2] [3] [4] [5] , which leads to the use of broadspectrum empirical antibiotic therapy in all patients meeting the HCAP criteria. These critera include any patient who: has been hospitalized in an acute-care hospital for ≥ 2 days within 90 days of the infection, has resided in a nursing home or a long-term care facility, has received recent intravenous antibiotic therapy, chemotherapy or wound care within the 30 days prior to the current infection or has attended a hospital or hemodialysis clinic [2] .
Several studies have reported conflicting data on the frequency of multidrug-resistant bacteria [6] [7] [8] [9] [10] [11] . Although patients who meet the criteria of HCAP are more susceptible to infection by drug-resistant pathogens, the majority of patients diagnosed with HCAP are not truly infected [6] [7] [8] [9] [10] [11] [12] . In addition, not all risk factors for HCAP may be equivalent in predicting pneumonia caused by drug-resistant pathogens [12] [13] [14] . Risk stratification models to identify patients who are likely to be infected with multidrug-resistant pathogens have therefore been developed [13] [14] [15] [16] [17] . All of these studies included patients with immunosuppression as a risk factor for HCAP, but this group was excluded from the ATS/IDSA guidelines because immunosuppression is associated with severe respiratory infection and infection by opportunistic pathogens [2] . In other guidelines, different initial empirical antibiotic therapy has been suggested [18, 19] . This means that the risk factors of drug-resistant pathogens in patients with pneumonia developed outside the hospital need to be reevaluated after excluding the patients with immunosuppression according to the ATS/IDSA.
The objectives of this study were to evaluate the risk factors for acquiring drug-resistant pathogens among immunocompetent patients coming from the community who were hospitalized with pneumonia, and to develop risk stratification models to identify patients with pneumonia caused by drug-resistant pathogens. We also compared the discrimination powers of the risk stratification models to those of the HCAP criteria suggested by the ATS/IDSA.
Patients and Methods
For all consecutive adult patients with pneumonia at the Samsung Medical Center (a 1,961-bed, university-affiliated, tertiary referral hospital in Seoul, South Korea) between January 2008 and December 2011, data were collected and retrospectively analyzed.
Some of the clinical data for patients are included in other articles [8, 20] . The study was approved by the institutional review board of the Center with regard to the review and publishing of information obtained from patient records. Informed consent was waived because of the retrospective nature of the study.
Study Population
Over the study period, all consecutive patients admitted to the hospital via the emergency department with pneumonia were prospectively registered. The patients with HAP that developed after having been hospitalized for >72 h or within 10 days of leaving the hospital were not included [7] . Patients who had been transferred after hospitalization for >48 h in other hospitals were excluded. Immunocompromised patients, such as those with neutropenia (i.e. an absolute neutrophil count of <1,500/mm 3 ) after chemotherapy or HIV infection and those who had undergone transplantations, were also excluded [2] .
During the study period, 2,187 consecutive patients with pneumonia were hospitalized via the emergency department. Of these, we excluded 563 patients with HAP, 315 who were immunocompromised and 95 who had been transferred from other hospitals after hospitalization for >48 h. Thus, in total, 1,214 patients hospitalized with pneumonia were eligible for this study, consisting of 680 (56%) with CAP and 534 (44%) with HCAP. The etiologic pathogen of the pneumonia could be identified in 155 HCAP patients (29%) and 160 CAP patients (24%) (p = 0.030). A total of 315 patients were included in the analysis.
Diagnosis of CAP and HCAP
A clinical diagnosis of pneumonia required the presence of new radiographic infiltrates and at least 2 of the following clinical criteria: fever (>38 ° C) or hypothermia ( ≤ 35 ° C), new cough with or without sputum production, pleuritic chest pain, dyspnea and altered breath sounds on auscultation [21] . The patients with pneumonia were classified into the CAP and HCAP groups. HCAP was defined as a diagnosis of pneumonia in patients admitted to the hospital who met at least 1 of the following criteria: (1) a recent history of hospitalization for ≥ 2 days in the preceding 90 days, (2) residence in a nursing home or long-term care facility, (3) recent antibiotic therapy, intravenous chemotherapy or wound care within the 30 days prior to the current infection and (4) attendance at a hospital or hemodialysis clinic [2, 7] . CAP was defined as a diagnosis of pneumonia in patients who did not meet any of the criteria for HCAP.
Data Collection
Based on patient demographics and baseline clinical data that were prospectively registered, pneumonia severity was also evaluated using the Pneumonia Severity Index (PSI) and the CURB-65 (confusion, urea nitrogen, respiratory rate, blood pressure, age ≥ 65 years) [22, 23] . A clinical diagnosis of severe pneumonia was made according to the previous criteria [24] . Functional status was assessed using the system developed by the Eastern Cooperative Oncology Group (ECOG) [25] .
Microbiologic Data and Antibiotic Treatment
Microorganisms were identified in a microbiology laboratory. Antimicrobial susceptibility testing was performed by the GNI card in a VITEK II automated system (bioMérieux, Hazelwood, Mo., USA) using the modified-broth microdilution method or the disk diffusion method, according to the recommendations of the Clinical and Laboratory Standards Institute. Strains showing intermediate antimicrobial susceptibility profiles were considered to be resistant.
An etiologic diagnosis was considered when a respiratory pathogen was isolated from a usually sterile specimen, pneumococcal antigen was detected in urine or a predominant microorganism was isolated from adequate sputum or bronchial washing fluids with compatible Gram-staining, as previously reported [8, 20] . Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas sp., Acinetobacter sp., Stenotrophomonas maltophilia and extended-spectrum β-lactamase-producing Enterobacteriaceae were considered potentially drug-resistant (PDR) pathogens [5] .
Initial antibiotic therapy during the study period recommended a combination of β-lactams plus macrolides for patients with CAP and a combination of antipseudomonal β-lactams plus fluoroquinolones for patients with HCAP or those with a high risk of pseudomonal infection. In our institution, additional vancomycin or linezolid was not recommended for the initial treatment of CAP or HCAP because of the low prevalence of MRSA occurrence in patients with these types of pneumonia.
The appropriateness of antibiotic treatment was analyzed for all cases with an etiologic diagnosis according to susceptibility test criteria for lower respiratory tract pathogens. Antibiotic treatment was classified as inappropriate if the initially prescribed antibiotics were not active against the identified pathogens, based on in vitro susceptibility testing [4] .
Statistical Analyses
To identify the risk factors independently associated with PDR pathogen occurrence, we conducted a multivariate analysis using a logistic regression model with backward stepwise selection with p < 0.05 for entry of variables and p > 0.10 for removal of variables that identified independent predictors of PDR pathogens. Initial candidate variables were those with p < 0.25 in the univariate analyses and a priori variables of HCAP criteria suggested by the ATS/ IDSA [26] . Variables were assessed for collinearity, and the goodness-of-fit of the model was evaluated with the Hosmer-Lemeshow test.
From the logistic regression findings, a score-based predictive scoring system was developed [27] . To generate a simple integerbased point score for each predictor variable, we assigned scores by dividing the β coefficients by the absolute value of the smallest coefficient in the final model and rounding up to the nearest integer. The total score for each participant was calculated by adding each component together. We then explored the predictive value of the point score for correctly indicating the presence of infection with a PDR pathogen using a receiver operating characteristic (ROC) curve, and validated the prediction rule internally, using the bootstrap method in the original data set by sampling with replacement for 1,000 iterations. The estimated area under the curve (AUC) values for the presence of HCAP criteria, the presence of identified risk factors for PDR pathogens and the new predictive score were compared using the Hanley-McNeil test with the Bonferroni correction [28] .
All tests were 2-sided and p < 0.05 was considered significant. The data were analyzed using PASW Statistics 18 (SPSS Inc., Chicago, Ill., USA) for descriptive analysis and STATA 11 (STATA Corp, College Station, Tex., USA) for ROC analysis.
Results

Patient Characteristics
The baseline characteristics of patients with HCAP and CAP are presented in table 1 . Patients with HCAP had more comorbidities and a worse functional status than patients with CAP. Septic shock at presentation was higher in HCAP patients than in CAP patients, although the admission rate to the ICU of the 2 groups did not dif- (35) 27 (17) 22 (14) 15 (10) 16 (10) 12 (8) 2 (1) 33 (21) 65 (41) 36 (23) 31 (19) 12 (8) 10 (6) 12 (8) (14) 33 (21) 32 (21) 45 (29) 46 (29) 17 (11) 19 (12) 23 (14) The data are presented as medians (interquartile ranges) or n (%). fer. In addition, the median PSI score was higher in HCAP patients than in CAP patients, in contrast to the median CURB-65 severity score.
The median length of antibiotic treatment and hospital stay were significantly longer in HCAP patients than in CAP patients (p = 0.018 and p < 0.001, respectively). Hospital mortalities were 21% in HCAP patients and 8% in CAP patients (p = 0.001).
Pathogen Distribution
The distributions of pathogens are shown in table 2 . Overall, Streptococcus pneumoniae was the most frequently isolated pathogen in our patients. PDR pathogen occurrence was significantly higher in HCAP patients than in CAP patients (32 vs. 15%, p < 0.001). However, there was no significant difference in inappropriate initial antibiotic treatment between groups (14 vs. 10%, p = 0.328).
The baseline characteristics of patients infected or not infected with PDR pathogens are presented in table 3 . Patients with PDR pathogens had worse functional status and were more likely to meet at least 1 of the HCAP criteria. Nonetheless, 33% of patients with PDR pathogens did not meet the HCAP criteria, but 44% of patients without PDR pathogens did. Although the HCAP criteria were more prevalent in patients with PDR pathogens, not every HCAP criterion contributed equally to this distribution. The prevalence rates of recent chemotherapy, hemodialysis and wound care were similar between groups.
Logistic regression analysis identified 5 variables that were independently associated with the identification of PDR pathogens ( table 4 ) ( table 4 ) . In addition, poor functional status (ECOG ≥ 3) (adjusted OR 2.904 and 95% CI 1.516-5.564, p = 0.001) and chronic lung disease (adjusted OR 1.970 and 95% CI 1.075-3.612, p = 0.028) were also independently associated with the recovery of PDR pathogens.
Based on the logistic regression analysis, we created a new predictive scoring system using the β coefficients ( table 4 ). A β coefficient of 0.678 corresponded to approxi- (17) 10 (6) 23 (15) 6 (4) 4 (3) 2 (1) 7 (5) 16 (10) 3 (2) 6 (4) 91 ( (6) 13 (8) 20 (13) 1 (1) 2 (1) 2 (1) 11 (7) 12 (8) 7 (4) Data are presented as n (%). PDR pathogens include MRSA, Pseudomonas sp., Acinetobacter sp., S. maltophilia and extended-spectrum β-lactamase-producing Enterobacteriaceae. MSSA = Methicillin-sensitive S. aureus. 49 (67) 32 (44) 27 (37) 10 (14) 7 (10) 3 (4) 1 (1) 106 (44) 53 (22) 33 (14) 44 (18) 6 (2) 7 (3) 1 (0) <0 (40) 37 (51) 15 (21) 12 (16) 8 (11) 7 (10) 2 (3) 1 (1) 212 (88) 99 (41) 83 (34) 48 (20) 41 (17) 19 (8) 19 (8) 22 (9) fig. 1 ). Among patients with <1 point, the prevalence of PDR pathogens was <5%, compared with prevalence rates of 28% in patients with scores ranging from 1 to 3 and >60% in patients with scores of ≥ 4 (p < 0.001 for trend). The ROC curves for the risk of PDR pathogens for the presence of HCAP criteria, the presence of identified risk factors for PDR pathogens and the new predictive score are shown in figure 2 . The new predictive score had good predictive value with an AUC of 0.756 (95% CI 0.698-0.815), which was similar to 0.745 (95% CI 0.678-0.813), the average AUC obtained from internal validation. Moreover, this scoring system had a higher discriminatory power to predict the risk of PDR pathogens than the presence of HCAP criteria (AUC 0.617 and 95% CI 0.554-0.679) and the number of HCAP criteria (AUC 0.670 and 95% CI 0.628-0.713) (p < 0.001 for both factors). 
Discussion
This study evaluated the risk factors for acquiring PDR pathogens among immunocompetent patients coming from the community who were hospitalized with pneumonia. A risk stratification model to identify patients with pneumonia caused by PDR pathogens was also developed. One third of the patients with pneumonia caused by PDR pathogens did not meet the criteria for HCAP, but the majority of patients who met the criteria -especially those who had recently had chemotherapy, hemodialysis or wound care -had no PDR pathogens. We also found that poor functional status and chronic lung disease were significantly associated with PDR pathogens. However, the risk factors identified were not equivalent in predicting PDR pathogens, and a risk stratification model was more accurate than the presence of the risk factors or the HCAP criteria for assessing the probability of PDR pathogens.
Previous studies have documented the increasing prevalence of drug-resistant pathogens in pneumonia developed in the community. In retrospective microbiological studies from the USA [3, 4] , PDR pathogens such as MRSA, Pseudomonas sp. and Acinetobacter sp. were common in HCAP patients. These results support the ATS/ IDSA recommendation for the use of broad-spectrum empirical antibiotic therapy in all patients who meet the HCAP criteria. However, subsequent studies have reported conflicting data on the frequency of multidrug-resistant bacteria [6] [7] [8] [9] [10] [11] . Although patients who meet the HCAP criteria have a greater risk for multidrug-resistant bacteria, the majority of patients diagnosed with HCAP are not truly infected with multidrug-resistant pathogens. Consequently, broad-spectrum empirical antibiotic therapy according to the ATS/IDSA may not be adequate and can even constitute overtreatment. In this study, guideline-concordant treatment could not be shown to be associated with improved outcomes [29] [30] [31] . Therefore, precise risk stratification rather than HCAP criteria for PDR pathogens would provide better identification of patients infected with these pathogens.
Previous studies evaluated additional risk factors for drug-resistant pathogens in patients with pneumonia [13] [14] [15] [16] [17] ; however, all of these studies included patients with any type of immunosuppression. They also evaluated the predictive potential of an HCAP definition for the presence of PDR pathogens, but the performance of the HCAP criteria was poor for predicting patients likely to be infected with drug-resistant pathogens [13] [14] [15] . Moreover, several HCAP criteria, such as recent chemotherapy and wound care, were not associated with drugresistant pathogens; our results are consistent with this. Subsequent studies also confirmed that not all HCAP criteria are associated with drug-resistant pathogens [16, 17] . However, hospitalization in the preceding 90 days was consistently and independently associated with the identification of drug-resistant pathogens [13] [14] [15] [16] [17] . In addition, residents in nursing homes or long-term care facilities and with prior antibiotic exposure were also significantly associated. Consistent with these previous studies, our study found that nursing home residency, previous hospitalization and prior antibiotic therapy were major independent predictors for PDR pathogens.
We also found poor functional status to be an independent risk factor for PDR pathogens in our cohort. This association has been previously demonstrated in patients with nursing home-acquired pneumonia, which is the most important subgroup within the HCAP definition [32] . In other HCAP studies [5, 9] , enteral-tube feeding, which indicates increased requirements for patient care, was predictive of infection with drug-resistant pathogens. These associations have been explained by the fact that patients with poor functional status or enteral-tube feeding are more likely to be exposed to the cross-contamination of bacteria due to their increased requirements for care [32] . Therefore, functional status should also be assessed in the evaluation of risk factors for PDR pathogens [1, 33] .
Given the limits of the current HCAP criteria, more restrictive risk stratification approaches to improve the risk-benefit balance associated with prescribing broadspectrum antibiotic therapy have been proposed [13] [14] [15] [16] [17] . Until now, the identified risk factors for drug-resistant pathogens were weighted differently, so risk stratification scoring tools showed better predictions of infection by drug-resistant pathogens than the current HCAP criteria [34, 35] . Consistent with previous reports, our risk stratification model based on differently weighted predictors is more accurate than the presence of the identified risk factors or the HCAP criteria for assessing the probability of PDR pathogens. Patients at a low risk for acquiring PDR pathogens who were identified based on our risk stratification model had a low prevalence of PDR pathogen infection, so the adoption of this model could lead to fewer patients unnecessarily receiving broad-spectrum antibiotic therapy. However, our model still needs to be validated, internally and externally [34] .
The strength and novelty of our study rely on a specific analysis of all risk factors for acquiring PDR pathogens, including comorbidities and functional status, in a 197 relatively large population of consecutive immunocompetent patients with pneumonia developed in the community. However, it does have several potential limitations that should be acknowledged. First, given the retrospective nature of the analysis, there is always the possibility that selection bias might have influenced the significance of our findings. However, the data were collected prospectively from all consecutive pneumonia patients admitted to the hospital via the emergency department. Second, we analyzed only patients with culture-positive pneumonia. Therefore, our findings may have been skewed in that many cases of pneumonia may have negative culture results. Nevertheless, because we aimed to evaluate risk factors for predicting PDR pathogens, by necessity we had to rely on the data of patients who had had a respiratory pathogen isolated. Patients with culture-negative pneumonia have a lower severity of illness than those with culture-positive pneumonia [36] . Therefore, our results cannot be generalized to patients who may have had negative culture results. Third, the number of patients residing in a nursing home was relatively small in our cohort. This is a result of the distinct features of tertiary referral hospitals according to the healthcare system in Korea [9, 37] . Nevertheless, nursing home residency was the main factor leading to PDR pathogen acquisition. Finally, our study was from a single institution with a comprehensive cancer center, so there was a large number of cancer patients on chemotherapy. Although immunosuppressed patients with neutropenia that had developed after chemotherapy were excluded, this situation could limit the generalizability of our findings to other hospitals that have less cancer patients with pneumonia.
In conclusion, functional status, pulmonary comorbidity, nursing home residency, previous hospitalization and prior antibiotic therapy were significantly associated with acquiring PDR pathogens in immunocompetent patients with pneumonia developed outside of the hospital. However, the risk factors identified were not equivalent in predicting PDR pathogens. Therefore, a risk stratification model may be more accurate than the presence of the risk factors or HCAP criteria for assessing the probability of PDR pathogens.
